Claims for Patent: 9,895,359

Summary for Patent: 9,895,359

Title:	Inhibition of crystal growth of roflumilast
Abstract:	Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in patient in need of such treatment.
Inventor(s):	Osborne; David W. (Fort Collins, CO)
Assignee:	ARCUTIS, INC. (Menlo Park, CA)
Application Number:	15/616,409
Patent Claims:	1. A method for inhibiting roflumilast crystal growth or changes in particle size in a composition, comprising including hexylene glycol in a composition comprising roflumilast. 2. The method according to claim 1, wherein said composition comprises suspended roflumilast particles. 3. The method according to claim 2, wherein changes in the size of the suspended roflumilast particles is inhibited during storage for six weeks at 20-26.degree. C. 4. The method according to claim 1, wherein said hexylene glycol is added in an amount of 0.1-20% w/w. 5. The method according to claim 4, wherein said hexylene glycol is added in an amount of 0.5-2% w/w. 6. The method according to claim 1, wherein said roflumilast composition comprises 0.005-2% roflumilast. 7. The method according to claim 1, wherein said roflumilast composition is selected from the group consisting of an oil in water emulsion, a thickened aqueous gel, a thickened hydroalcoholic gel, a hydrophilic gel, and a hydrophilic or hydrophobic ointment. 8. The method according to claim 1, wherein said roflumilast composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, surfactant or emulsifier, polymer or thickener, antifoaming agent, preservative, antioxidant, sequestering agent, stabilizer, buffer, pH adjusting solution, skin penetration enhancer, film former, dye, pigment, and fragrance. 9. The method according to claim 1, wherein said roflumilast composition further comprises an additional active agent selected from the group consisting of anthralin, azathioprine, tacrolimus, coal tar, methotrexate, methoxsalen, salicylic acid, ammonium lactate, urea, hydroxyurea, 5-fluorouracil, propylthouracil, 6-thioguanine, sulfasalazine, mycophenolate mofetil, fumaric acid esters, corticosteroids, corticotropin, vitamin D analogues, acitretin, tazarotene, cyclosporine, resorcinol, colchicine, adalimumab, ustekinumab, infliximab, bronchodialators, and antibiotics. 10. The method according to claim 1 wherein said hexylene glycol is added to said composition prior to storage. 11. The method according to claim 1, wherein said composition comprises one or more carriers suitable for topical, parenteral or pulmonary administration. 12. The method according to claim 1, wherein said composition comprises one or more carriers suitable for topical administration. 13. The method according to claim 1, further comprising adding diethylene glycol monoethyl ether to said composition. 14. The method according to claim 1, wherein said composition comprises roflumilast, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben, and purified water. 15. The method according to claim 14, wherein the composition comprises: TABLE-US-00002 roflumilast 0.5% w/w white petrolatum 10.0% w/w isopropyl palmitate 5.0% w/w cetearyl alcohol, dicetyl 10.0% w/w phosphate, and ceteth-10 phosphate hexylene glycol 2.0% w/w diethylene glycol 25.0% w/w monoethyl ether methylparaben 0.2% w/w propylparaben 0.05% w/w, and purified water q.s. ad 100 (47.25%). 16. The method according to claim 4, wherein said hexylene glycol is added in an amount of 0.25-8% w/w.

Details for Patent 9,895,359

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2039-02-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2039-02-26